GlassScriptPhysician profile
Tiffany Burca
NPI 1790071835
$989.39
in general payments reported to CMS, 2019-2025
15 companies · $18.55 in 2025
The $18.55 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $696 · 2024: $275 · 2025: $18.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $235.69 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $226.28 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $157.31 | 2023-2024 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $82.30 | 2023-2024 | |
| Astellas Pharma US INC | $47.68 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $41.07 | 2023-2024 | Farxiga |
| Abbott Laboratories | $41.05 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $34.80 | 2023 | Trelegy Ellipta |
| Amgen INC. | $21.14 | 2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $19.56 | 2023 | |
| Ibsa Pharma INC. | $18.62 | 2023 | Tirosint, Licart |
| Exact Sciences Corporation | $17.94 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.64 | 2023 | Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $15.61 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2024 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Burca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.